RANK (receptor activator of NF­κB), also known as CD265 and ODFR, is a single-pass type I membrane glycoprotein in the tumor necrosis factor receptor superfamily (TNFRSF11A). RANK contains 4 TNFR cysteine-rich repeats in the extracellular region but lacks a cytoplasmic death domain (DD). RANK is ubiquitously expressed with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. TRANCE (TNF­related activation­induced cytokines), also known as OPGL (osteoprotegerin ligand) and ODF (osteoclast differentiation factor), is the ligand for RANK (RANKL). RANK and RANKL are important regulators of the interaction between T cells and dendritic cells for the enhancement of T cell growth and dendritic cell function. They are also essential mediators for osteoclast and lymph node development. Mutations in RANK are associated with familial expansile osteolysis (FEO), Paget disease of bone type 2 (PDB2), and osteopetrosis autosomal recessive type 7 (OPTB7). FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. OPTB7 is characterized by abnormally dense bone, due to defective resorption of immature bone. Soluble RANK is able to block RANKL-induced biological activity. RANK can interact with various TRAF family proteins, through which this receptor induces the activation of NF-­κB and JNK pathways.

RANK (receptor activator of NF­κB), also known as CD265 and ODFR, is a single-pass type I membrane glycoprotein in the tumor necrosis factor receptor superfamily (TNFRSF11A). RANK contains 4 TNFR cysteine-rich repeats in the extracellular region but lacks a cytoplasmic death domain (DD). RANK is ubiquitously expressed with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. TRANCE (TNF­related activation­induced cytokines), also known as OPGL (osteoprotegerin ligand) and ODF (osteoclast differentiation factor), is the ligand for RANK (RANKL). RANK and RANKL are important regulators of the interaction between T cells and dendritic cells for the enhancement of T cell growth and dendritic cell function. They are also essential mediators for osteoclast and lymph node development. Mutations in RANK are associated with familial expansile osteolysis (FEO), Paget disease of bone type 2 (PDB2), and osteopetrosis autosomal recessive type 7 (OPTB7). FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. OPTB7 is characterized by abnormally dense bone, due to defective resorption of immature bone. Soluble RANK is able to block RANKL-induced biological activity. RANK can interact with various TRAF family proteins, through which this receptor induces the activation of NF-­κB and JNK pathways.

  

Product Details

 

Gene Symbol: TNFRSF11A; CD265; FEO; OFE; ODFR; OSTS; PDB2;   OPTB7; TRANCER; LOH18CR1

  

NCBI Gene ID: 8792

 

Uniprot Entry: Q9Y6Q6

 

Construct Details: The recombinant human RANK-Fc fusion is expressed as a 411 amino acid protein consisting of Ile30 - Pro212 region of RANK (UniProt accession #Q9Y6Q6) and a C-terminal Fc from human IgG1, which exists as a dimer/tetramer/oligomer under non-reducing conditions (see the gel image inserted above).  

  

Source: Human cells stably expressing human RANK-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

 

        10         20         30         40         50         60 

 

IAPPCTSEKH YEHLGRCCNK CEPGKYMSSK CTTTSDSVCL PCGPDEYLDS WNEEDKCLLH 

 

        70         80         90        100        110        120 

 

KVCDTGKALV AVVAGNSTTP RRCACTAGYH WSQDCECCRR NTECAPGLGA QHPLQLNKDT 

 

       130        140        150        160        170        180 

 

VCKPCLAGYF SDAFSSTDKC RPWTNCTFLG KRVEHHGTEK SDAVCSSSLP ARKPPNEPHV  

 

       190        200        210        220        230        240 

 

YLPSTGTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN  

 

       250        260        270        280        290        300 

 

WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI 

 

       310        320        330        340        350        360 

 

SKAKGQPREP QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 

 

       370        380        390        400        410 

 

VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K 

 

M.W.: Calculated molecular mass (kDa): 45.7; Estimated by SDS-PAGE under reducing condition (kDa): ~55

 

Calculated PI: 7.23

 

Calculated extinction coefficients (M-1 cm-1, at 280nm):  62475

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand human RANKL and inhibits RANKL­-induced signaling activity including osteoclast differentiation in mouse monocyte/macrophage cells RAW 264.7. 

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Nature 390:175 (1997).

2. J. Biol. Chem. 273: 20551 (1998). 

3. J. Biol. Chem. 273: 34120 (1998).

4. Nat. Genet. 24:45 (2000).

5. Am. J. Hum. Genet. 83:64 (2008).

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0281-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.